Who owns GEVA - SYNAGEVA BIOPHARMA CORP - COM based on 13F filings?

Open this security page to review the newest available 13F ownership history, top reported holders, and period-by-period changes.

SYNAGEVA BIOPHARMA CORP - COM (GEVA) Institutional Ownership

Q: What is CUSIP 87159A103?

CUSIP 87159A103 is the security identifier used in SEC filing datasets for GEVA - SYNAGEVA BIOPHARMA CORP - COM.

CUSIP: 87159A103

13F Institutional Holders and Ownership History from Q1 2014 to Q2 2015

Type / Class: Equity / COM
Symbol: GEVA

Reported Shares, Excluding Options vs Price

Reported Value, Excluding Options

Total Investors

Investment Quick Answers

What is CUSIP 87159A103?
CUSIP 87159A103 identifies GEVA - SYNAGEVA BIOPHARMA CORP - COM in SEC 13F datasets.

Where can I see the latest institutional holders?
Use the ownership history tables below to review the newest available institutional filing periods.

Continue Investment Research

Latest 13F filings for new institutional portfolio disclosures.
Latest Schedule 13D/13G reports for activist and beneficial ownership updates.
Latest 10-Q/10-K reports to cross-check issuer fundamentals.
Recent insider transactions for management buying/selling context.
SEC investors directory and top value investors for manager-level discovery.
All institutional ownership pages to compare adjacent CUSIP pages.

Recent Quarterly Holder Reports

Open recent reporting periods for CUSIP 87159A103:

Q2 2015 (0 holders) Q1 2015 (128 holders) Q4 2014 (125 holders) Q3 2014 (117 holders) Q2 2014 (114 holders) Q1 2014 (115 holders)

Institutional Holders of SYNAGEVA BIOPHARMA CORP - COM (GEVA) across Reporting Periods

Period	Reported Shares, Excl. Options	Value, Excl. Options	Value Change	Puts Notional Value	Calls Notional Value	Price (Median)	Investors
2015 Q2	0	$0	-$3,887,854,161	$0	$0		0
2015 Q1	39,783,820	$3,879,829,171	+$341,044,448	$64,616,000	$17,840,000	$97.53	128
2014 Q4	36,287,425	$3,367,093,483	+$89,069,010	$12,582,000	$8,861,000	$92.79	125
2014 Q3	35,360,562	$2,432,115,004	+$108,259,962	$8,027,000	$3,865,000	$68.78	117
2014 Q2	33,479,591	$3,508,646,746	+$137,930,441	$46,069,000	$29,595,000	$104.80	114
2014 Q1	32,299,752	$2,679,570,505	+$144,996,936	$23,024,000	$11,200,000	$82.97	115